ALC Stock Analysis: Alcon | SW
Medical Instruments & Supplies | SW, Switzerland | Market Cap: 25.543m CHF | 12M Return: -11.9% | CH0432492467 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 50.2M
EPS Trend: 88.6%
Qual. Beats: 2
Rev. Trend: 99.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alcon Inc. is a Swiss-based global eye care company that operates two main business segments: Surgical and Vision Care. The Surgical segment provides equipment, instrumentation, diagnostics, intraocular lenses (IOLs), and related consumables used in cataract, vitreoretinal, and refractive procedures. The Vision Care segment offers daily disposable and reusable contact lenses, along with ocular health products addressing dry eye, allergies, glaucoma, and lens care. Founded in 1945 and headquartered in Geneva, the company serves customers worldwide.
The firm markets a broad portfolio of branded cataract surgery platforms, including the LenSx laser system, the NGENUITY 3D visualization system, and the ORA intra-operative measurement system, as well as delivery systems such as AutonoMe and UltraSert. In refractive surgery, its WaveLight platform supports the LASIK procedure. Alcon was formerly known as Alcon Universal S.A. and took its current name in December 2001.
As a large-cap constituent of the Health Care Equipment sub-industry, Alcon is one of the leading global players in the ophthalmic medical device and consumer eye care market, competing in a sector shaped by rising rates of cataracts, presbyopia, myopia, and other age-related vision conditions, alongside growing demand for advanced surgical equipment and premium IOLs.
- Aging demographics accelerate cataract procedure volume growth
- Premium IOL mix expansion lifts Surgical segment margins
- Contact lens competition pressures Vision Care pricing and share
| Net Income: 640.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.34 > 1.0 |
| NWC/Revenue: 32.17% < 20% (prev 38.72%; Δ -6.55% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.27b > Net Income 640.6m |
| Net Debt (4.43b) to EBITDA (2.33b): 1.90 < 3 |
| Current Ratio: 2.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (488.7m) vs 12m ago -1.85% < -2% |
| Gross Margin: 56.83% > 18% (prev 55.13%; Δ 1.70% > 0.5%) |
| Asset Turnover: 34.44% > 50% (prev 31.94%; Δ 2.50% > 0%) |
| Interest Coverage Ratio: 5.34 > 6 (EBIT TTM 1.11b / Interest Expense TTM 207.4m) |
| DSRI: 0.97 (Receivables 2.11b/2.02b, Revenue 10.8b/10.0b) |
| GMI: 0.97 (GM 55.13% / 56.83%) |
| AQI: 0.97 (AQ_t 0.62 / AQ_t-1 0.64) |
| SGI: 1.07 (Revenue 10.8b / 10.0b) |
| TATA: -0.05 (NI 640.6m - CFO 2.27b) / TA 31.2b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at CHF 53.14 with a total of 851,975 shares traded. Over the past week, the price has changed by +0.57%, over one month by -4.94%, over three months by -1.67% and over the past year by -11.91%.
Current recommended Stop Loss: 50.20 (which is 5.5% or 2.8 ATR below the current price).
Alcon has no consensus analysts rating.
Market Cap USD = 30.8b (25.5b CHF * 1.2042 CHF.USD)
P/E Trailing = 48.4771
P/E Forward = 16.3399
P/S = 2.3518
P/B = 1.4729
P/EG = 1.1668
Revenue TTM = 10.8b USD
EBIT TTM = 1.11b USD
EBITDA TTM = 2.33b USD
Long Term Debt = 4.15b USD (from longTermDebt, last quarter)
Short Term Debt = 652.8m USD (from shortTermDebt, last quarter)
Debt = 5.89b USD (from shortLongTermDebtTotal, last quarter) + Leases 580.0m
Net Debt = 4.43b USD (calculated: Debt 5.89b - CCE 1.46b)
Enterprise Value = 35.2b USD (30.8b + Debt 5.89b - CCE 1.46b)
Interest Coverage Ratio = 5.34 (Ebit TTM 1.11b / Interest Expense TTM 207.4m)
EV/FCF = 20.55x (Enterprise Value 35.2b / FCF TTM 1.71b)
FCF Yield = 4.87% (FCF TTM 1.71b / Enterprise Value 35.2b)
FCF Margin = 15.89% (FCF TTM 1.71b / Revenue TTM 10.8b)
Net Margin = 5.95% (Net Income TTM 640.6m / Revenue TTM 10.8b)
Gross Margin = 56.83% ((Revenue TTM 10.8b - Cost of Revenue TTM 4.65b) / Revenue TTM)
Gross Margin QoQ = 59.33% (prev 56.36%)
Tobins Q-Ratio = 1.13 (Enterprise Value 35.2b / Total Assets 31.2b)
Interest Expense / Debt = 3.52% (Interest Expense 207.4m / Debt 5.89b)
Taxrate = 13.28% (98.1m / 738.7m)
NOPAT = 959.7m (EBIT 1.11b * (1 - 13.28%))
Current Ratio = 2.09 (Total Current Assets 6.64b / Total Current Liabilities 3.18b)
Debt / Equity = 0.27 (Debt 5.89b / totalStockholderEquity, last quarter 21.7b)
Debt / EBITDA = 1.90 (Net Debt 4.43b / EBITDA 2.33b)
Debt / FCF = 2.59 (Net Debt 4.43b / FCF TTM 1.71b)
Total Stockholder Equity = 22.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.05% (Net Income 640.6m / Total Assets 31.2b)
RoE = 2.91% (Net Income TTM 640.6m / Total Stockholder Equity 22.0b)
RoCE = 4.23% (EBIT 1.11b / Capital Employed (Equity 22.0b + L.T.Debt 4.15b))
RoIC = 3.41% (NOPAT 959.7m / Invested Capital 28.1b)
WACC = 5.78% (E(30.8b)/V(36.7b) * Re(6.30%) + D(5.89b)/V(36.7b) * Rd(3.52%) * (1-Tc(0.13)))
Discount Rate = 6.30% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -79.45 | Cagr: -0.71%
[DCF] Terminal Value 76.18% ; FCFF base≈1.67b ; Y1≈1.76b ; Y5≈2.05b
[DCF] Fair Price = 56.20 (EV 31.6b - Net Debt 4.43b = Equity 27.2b / Shares 483.4m; r=8.35% [WACC [floored]]; 5y FCF grow 5.82% → 2.50% )
EPS Correlation: 88.60 | EPS CAGR: 7.50% | SUE: 2.47 | # QB: 2
Revenue Correlation: 98.98 | Revenue CAGR: 5.22% | SUE: 0.02 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.89 | Chg30d=+0.46% | Revisions=-10% | Analysts=13
EPS current Year (2026-12-31): EPS=3.49 | Chg30d=-0.05% | Revisions=+0% | GrowthEPS=+13.8% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=4.38 | Chg30d=+0.82% | Revisions=-12% | GrowthEPS=+25.2% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: -11% (up=7, down=9)